CSL chairman to step down in March 2027
Key points
- Gordon Naylor will take over as Chair of CSL on March 31, 2027, following Dr Brian McNamee AO's retirement.
- CSL share price closed up at $196.70 following recent operational updates.
- The leadership transition aims to ensure strong governance and continuity across CSL's plasma and vaccine operations.
CSL (ASX:CSL) announced that Dr Brian McNamee AO will retire from the board on March 31, 2027.
The board unanimously elected Gordon Naylor as the next chair to lead the company forward.
"Brian leaves big shoes to fill, and few people understand plasma, vaccines and this company as well as Gordon," said CSL Senior Independent Director Carolyn Hewson AO.
Mr Naylor will continue as Interim CEO until Feb. 1, 2027, before transitioning back to the board as chair elect alongside incoming CEO Deborah Waterhouse.
Following the announcement, the CSL share price was up at $196.70.
The leadership change reflects a structured succession plan to maintain stable oversight for global biopharmaceutical operations.
The board also appointed Carolyn Hewson, AO, as senior independent director effective March 31, 2027.
Frequently asked questions
More from Australia
Resurgent inflation pressures test key Australian consumer shares
The digital cart rush redefining Australian retail profit pools
Trans-Tasman insurers battle contract churn while defending profit margins
Capital battles heat up as takeover offers challenge listed housing operators
The equities fueling the next infrastructure supercycle
Crypto networks collide with sanctions in a fight for financial access
